Hummingbird Bioscience

Cancer and autoimmune diseases cause over 10 million deaths every year (Source: WHO). Existing therapies often harm healthy cells, causing serious side effects – and developing better treatments can take more than a decade, often without success.

Hummingbird Bioscience is creating next-generation antibody-based medicines that target diseased cells with precision. Using advances in AI, biology, and chemistry, the company has built powerful discovery platforms.

With over 100 patents filed, it has secured nearly half a billion dollars through investments and licensing deals – advancing clinical trials worldwide and bringing precision medicine closer to patients.